Abstract Very few registries worldwide focus on clinical outcomes of stem cell therapy (SCT) as the large number of applications and rapid development of the field complicates registry design considerably. The National Stem Cell Therapy Patient Registry of Malaysia aims to accommodate this by using a main protocol which covers the overall design and administration of the registry, and conditionspecific sub-protocols which deal with outcome measures. The registry will start with a few sub-protocols covering existing modes of SCT in Malaysia, with new sub-protocols released periodically as the need arises.
Introduction
Stem cell therapy (SCT) is relatively new in Malaysia. In spite of this, the great potential inherent in SCT has generated significant interest both within the medical profession and amongst the general public, which in turn has fed demand for provision of new clinical services.
Currently, only hemopoetic SCT is considered well established in Malaysia with its own set of national guidelines and a transplant registry [1] . All other modalities of SCT are considered experimental and need to be conducted under the aegis of the National Stem Cell Research and Ethics Sub-committee (NSCRES). They also should strictly adhere to the National Guidelines for Stem Cell Research and Therapy, which requires all therapeutic outcomes and adverse effects to be reported back to the NSCRES [2] .
While the current guidelines aim to limit the ethical and health risks arising from SCT, they do impose an administrative burden on SCT providers, some of whom are clinicians with busy practices. It is in the light of these developments that a coalition of SCT providers from the private sector began collaborating with the Clinical Research Centre (CRC) of the Malaysian Ministry of Health to set up the National Stem Cell Therapy Patient Registry (NSCTPR).
The registry purposes to gather long-term data on the efficacy and adverse outcomes of SCT. Data obtained from a registry complements that from clinical trials, which are better at monitoring events over a limited period. Pooled data from large numbers of patients can reveal trends that may not be evident from smaller numbers enrolled in clinical trials. In addition, real world data can be gathered on SCT which may differ in performance compared with the controlled environment of a clinical trial.
The SCT registry faces a number of challenges not found in other registries. The field is both novel and high-profile, with enormous potential for changing the future of medicine. Hence, great care must be taken to manage the risks in SCT to avoid the fate of gene therapy more than a decade ago [3] . The clinical indications for SCT are diverse and anticipated to multiply in the future. This is different from other registries which deal with a single indication and a more homogenous patient pool.
Materials and Methods

Study Objectives
The objectives of the registry are to determine the effectiveness of SCT, monitor safety and adverse events for products and services used in SCT, and to evaluate access to and quality of SCT performed at various clinical centers.
Inclusion and Exclusion Criteria
The study population consists of all patients who undergo SCT at registered clinical centers in Malaysia, both residents and non-residents. The inclusion criteria are deliberately broad to reflect real world practice and to ensure the sample is representative of the population undergoing SCT. Participation in the registry will be mandated through the legal authority provided by Private Healthcare Facilities and Services Act 1998 (PHFSA) [4] . All patients at participating clinical sites who meet the eligibility criteria are automatically enrolled in the registry. For purposes of this registry, SCT includes any products used for research or therapy in humans containing stem cells or progenitor cells permitted under current national guidelines [2] . SCT for hematological use is excluded as this is covered under another registry [1] .
Patients who are already or planned to be enrolled in clinical trials will be excluded from the registry as they will have to adhere to the trial regimen, which may differ from existing registry sub-protocols. In addition, data on efficacy and safety can also be obtained from the clinical trial, albeit with a shorter follow-up period.
Main and Sub-Protocols
The main protocol will cover the overall design and administration of the registry. Each disease or condition for which SCT is indicated will have its own sub-protocol. A sub-protocol should include the following sections: the scientific evidence justifying use of SCT in that condition, a primary outcome measure, a non-core dataset, and a statistical analysis plan specific to the sub-protocol. The registry will initially start with a few sub-protocols covering conditions for which SCT is currently employed in Malaysia, although this is projected to expand as the use of SCT becomes more widespread.
Each sub-protocol will be designed by a committee representing the major SCT providers in that field, who will have to agree on a common means of measuring clinical outcome, and yet accounting for individual variance in clinical practice. The main protocol and sub-protocols will each have to be submitted for formal ethics approval prior to implementation.
The primary outcome measure should be a good indicator of the severity of the condition as well as the efficacy of therapy. Preference should be given to a measure that is validated, widely utilized, and accepted by the medical community. The non-core dataset contains elements specific to the condition, which may prove useful to generate hypotheses or to explore other subsidiary questions not of primary interest to the registry. These should be kept to a minimum and be simple to measure (Table 1) .
Data Collection
The registry is designed as a multi-centre, observational cohort study to evaluate the health outcomes of patients undergoing SCT at participating clinical centers. The study population will consist of all patients from participating centers who fulfill the inclusion and exclusion criteria, beginning from the date of commencement of the registry or the individual centre's inclusion, whichever is later. The end date of recruitment would be the date of termination of the registry. It is anticipated that the registry will operate for at least 5 years, although this may be extended depending on new legislative or regulatory requirements. A waiver of informed consent has been obtained from the Malaysian Ministry of Health ethics review board. Participating clinical sites are however required to inform all its existing and prospective patients of their participation in the registry through a public notice prominently displayed on the premises.
Data for the registry will be collected when patients attend the clinical centers for normal treatment or follow-up visits, and be captured via an on-line system into a secure central database. In case of technical problems, data capture will be done through a backup paper-based system, which will be translated at a later date into the on-line system when circumstances permit.
All data will be divided into a core and non-core dataset ( Table 1 ). The core dataset consists of elements that are needed to address the key questions for which the registry was created. All patients enrolled into the registry will require this data to be entered, which will then be subject to quality control measures to ensure reliability and minimize missing data. The non-core dataset will mainly be detailed in the conditionspecific sub-protocols, although a few common elements will be retained as part of the main protocol. An accurate assessment of mortality can be obtained through record linkage with the national mortality database maintained by the National Registration Department.
Registry Organization
The registry is funded jointly by the CRC and healthcare establishments providing SCT. It is governed by an Advisory Board consisting of eminent SCT researchers and clinicians, including representatives of all major stakeholders. The Advisory Board is responsible for providing overall leadership and direction, oversee the progress, and ensure the continuing relevance of the registry.
The Steering Committee will comprise of independent experts in SCT, sponsor representatives, and an independent experienced statistician. It will be responsible for establishing policies and procedures for the running of the registry, reviewing safety data and interim results, and setting up the relevant sub-committees and expert panels.
To promote transparency, the NSCTPR will publish a report on its findings at least annually and disseminate it free of charge through its official website. In addition, information on the registry's objectives, organization, data collection methods, and scientific framework will also be made available through the same channel. Seed funding for the registry will be provided by CRC, but eventually it is anticipated that the registry will be self-funded through contributions from individual SCT providers.
Discussion
The release of the updated National Guidelines on SCT in August 2009 was a welcome milestone in the development of stem cell work in Malaysia. It provides a guide to both researchers and clinical providers as to the ethical and health-related expectations of the local regulatory bodies in this field. While these guidelines do not have the force of legislation, it was emphasized that failure to adhere could result in serious repercussions should any deficiency in medical care or ethics be uncovered [2] . Prior to release of the updated guidelines, there were already quite a number of local SCT providers. Some had well developed SCT practices with more than a hundred procedures performed annually, while others were only starting out. The stringent requirements imposed by the National Guidelines represent a steep barrier to entry of new SCT providers. This can potentially discourage innovation and research in this field, which is not what the guidelines intended [1] .
The CRC convened a meeting with some of the major SCT providers in private practice to work out the best way to help the providers comply with the guidelines while minimizing the administrative overhead. It was proposed that a NSCTPR would be able to meet most of these requirements. As each sub-protocol would have its own prior ethics approval, this would greatly facilitate the ethics review process for individual providers who adhere to the respective sub-protocols. In addition, collection and reporting of data on therapeutic outcomes and adverse effects could be undertaken on behalf of the providers.
There are a number of potential side-benefits from participation in the NSCTPR. Transparent reporting of results generates confidence in SCT providers from patients and regulatory authorities. This may also influence medical insurance reimbursement for SCT by providers with an established track record.
The main difficulty in design of the NSCTPR is in accommodating the wide diversity in the field. This is where the sub-protocols play a major role in that they allow the registry to start small and grow organically as new indications develop in the future. By engaging the major SCT providers in each field in sub-protocol design, this will encourage greater participation in the registry. Smaller providers will be able to use the sub-protocols as guides to their own practice, and this may eventually lead to consolidation around a smaller number of well-accepted SCT procedures.
Currently, most existing stem cell registries worldwide deal either with hematopoietic stem cells, human embryonic stem cell lines, or stem cell banks [5] [6] [7] . There are very few national registries covering clinical outcomes of SCT, likely due to the complexity of managing the diverse clinical indications as well as the rapidly changing nature of the field.
Issues During Implementation
There were a number of issues which we faced during implementation of the NSCTPR. The biggest difficulty was in convincing the various SCT providers that it was in their interest to work together. While overtly the NSCTPR offers them significant advantages, these benefits are delayed while they have to deal with the immediate administrative and cost overheads of registry participation. To overcome this, we approached key opinion leaders in each of the fields relevant to SCT and invited them to join either the Advisory Board or Steering Committee, and they in turn convinced their colleagues to participate.
The second issue which we faced was mandating participation through the PHFSA. While the Act clearly provides for this, it would not have been reasonable to begin implementation until the registry has been shown to be functional. In view of this, the Steering Committee decided to delay mandatory participation until the registry has at least a couple of sub-protocols with active recruitment of patients.
Another significant issue was the source of funding to maintain the registry over the anticipated operating lifespan. While the CRC provided seed funding, this was only sufficient to pay for a portion of the startup costs. To make up for the remainder, we had a choice of either obtaining this from individual clinical providers or from the laboratories which supply stem cells. In the end, we decided to source funding from the laboratories as they were few in number and collection of funds was correspondingly easier from a logistics perspective. We levied a fixed sum per patient that should only add about 1-2% to the total cost of SCT, but which is sufficient to operate the registry on a long term basis.
Some of the SCT providers had existing patients whom they wanted to enroll in the registry, but after consideration we decided on including only new patients. This is because there is a risk of selection bias and missing data when recruiting patients retrospectively, although at some future point we may allow this provided the results from these patients are analyzed and reported separately.
Finally, while our intent is for individual sub-protocols to be designed by the SCT providers themselves, in practice this is not easy to achieve. Most of the providers are busy clinicians with relatively little research experience, and we found that the first few sub-protocols required significant input from us including statistical support. However, we envisage that this issue should be less of a problem in the future as the initial sub-protocols act as a template for design of further sub-protocols.
Conclusion
The flexible design model used by the Malaysian NSCTPR enables it to adapt to the varied and rapidly progressing field of clinical stem cell work. It is hoped that by facilitating reporting of outcomes by SCT providers, it will encourage them to comply with existing national guidelines while upholding the highest standards of medical care and ethics.
